Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.63 |
| ▸ | HTR1D | P28221 | 4/20 | 0.63 |
| ▸ | HTR2C | P28335 | 3/20 | 0.63 |
| ▸ | HTR1B | P28222 | 3/20 | 0.63 |
| ▸ | MPO | P05164 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.63 |
| ▸ | HTR7 | P34969 | 2/20 | 0.63 |
| ▸ | HTR6 | P50406 | 2/20 | 0.63 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.63 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | CTSK | P43235 | 1/20 | 0.63 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL2533927 | 0.93 | HTR2C (0.57) | HTR2AHTR1DHTR2CHTR1BMPO | |
| SCHEMBL2536567 | 0.88 | LTA4H (0.67) | HTR2AHTR1DHTR2CHTR1BMPO | |
| SCHEMBL24144265 | 0.85 | HTR2A (0.57) | HTR2AHTR1DHTR2CHTR1BMPO | |
| SCHEMBL16433272 | 0.84 | IMPDH2 (0.52) | HTR2AHTR1DHTR2CHTR1BMPO | |
| SCHEMBL20120174 | 0.81 | GPR17 (0.56) | MAPTIMPDH2 | |
| Tryptamine SCHEMBL26725 | 0.78 | HTR2A (1.00) | HTR2AHTR1DHTR2CHTR1BMPO | |
| Tryptamine SCHEMBL8714244 | 0.78 | HTR2A (1.00) | HTR2AHTR1DHTR2CHTR1BMPO | |
| Tryptamine SCHEMBL29373222 | 0.78 | HTR2A (1.00) | HTR2AHTR1DHTR2CHTR1BMPO | |
| SCHEMBL2537606 | 0.78 | TRPM8 (0.80) | HTR2AHTR1DHTR2CHTR1BMPO | |
| Tryptamine SCHEMBL22127053 | 0.76 | HTR2A (0.96) | HTR2AHTR1DHTR2CHTR1BMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1859798-B1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2015-12-30 | — | — | EP | disclosed |
| US-8044090-B2 | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20090306110-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2009-12-10 | — | — | US | disclosed |
| EP-1859798-A1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1379239-B1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2007-05-03 | — | — | US | disclosed |
| US-7157488-B2 | N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | CHEN ZHAOGEN | 2006-01-12 | — | — | US | disclosed |
| CN-1610547-A | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor | LILLY CO ELI (US) | 2005-04-27 | — | — | CN | disclosed |
| EP-1379239-A2 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | HTR6, HTR2C, HTR1B | HTR2A 5/4885HTR1D 16/4885HTR2C 2/4885 |
| US-20090306110-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | HTR2A 5/4885HTR1D 16/4885HTR2C 2/4885 |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | HTR2A 5/4885HTR1D 16/4885HTR2C 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.